4-oxo-1,4-dihydroquinoline-3-carboxylic Acid CAS 13721-01-2: High-Purity Pharmaceutical Intermediate Manufacturer & Supplier

Discover the critical role of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid (CAS 13721-01-2) in advancing pharmaceutical research. As a leading manufacturer and supplier in China, we provide high-purity intermediates essential for developing innovative treatments, including novel HIV-1 integrase strand transfer inhibitors. Contact us for a quote and sample to ensure your project's success.

Get a Quote & Sample

Advantages of Sourcing from Us

Guaranteed Quality & Purity

Our 4-oxo-1,4-dihydroquinoline-3-carboxylic acid meets high purity standards, crucial for pharmaceutical formulation. We provide comprehensive documentation to support your regulatory requirements when you purchase this pharmaceutical intermediate.

Competitive Manufacturing Prices

Leverage our efficient manufacturing processes as a leading 4-oxo-1,4-dihydroquinoline-3-carboxylic acid manufacturer to obtain competitive pricing. Get a clear price quote for bulk orders.

Stable Supply Chain & Support

We ensure a consistent supply of this vital intermediate. As your dedicated CAS 13721-01-2 supplier, we offer technical support and swift delivery to keep your projects on track.

Key Applications in Pharmaceutical Development

HIV-1 Integrase Inhibitor Synthesis

This intermediate is a cornerstone in the synthesis pathway of novel HIV-1 integrase strand transfer inhibitors, aiding in the development of more effective antiviral therapies.

Drug Discovery & Research

Used extensively in research and development settings for exploring new chemical entities and optimizing drug candidates, making it a valuable asset for any R&D team.

Advanced Pharmaceutical Intermediates

As a versatile quinoline derivative, it serves as a crucial building block for a range of complex pharmaceutical molecules beyond HIV treatments.

Custom Synthesis Projects

We can support your custom synthesis requirements, offering reliable sourcing for this and related pharmaceutical intermediates from our China-based operations.